Abstract
Tat is a viral protein secreted from HIV infected cells and extra cellular Tat is suspected to prevent destruction of HIV infected cells from cells of the cellular immunity. The effect of anti retroviral therapy (ART) on Tat secretion has never been investigated. In this study, we tested for antibody reactivity against Tat variants representative of the main HIV subtypes in HIV positive patients receiving ART with undetectable viral loads ( < 40 copies/mL) over the course of one year with a blood sampling every three months. For each of theses five blood sampling, an average of 50 % of patients had Anti-Tat IgG, it turned out that 86% of patients could recognize Tat at least in one blood sampling during the course of the study. Amazingly, anti-Tat IgG appeared and/or disappeared in 66 % of patients. Only 20% had anti-Tat IgG remaining persistently while 14% were consistently without anti Tat IgG in the five blood sampling. No significant correlation was found between anti-Tat IgG and CD4+ T cell, CD8+ T cell and B cell counts revealing the incapacity of these anti Tat IgG to neutralize extra cellular Tat. Interestingly the absence and then the appearance of anti-Tat IgG in patients suggest the presence of HIV infected cells in the blood that may constitute a significant reservoir of HIV infected cells. As a conclusion antiretroviral therapy does not block the secretion of Tat and may explain why HIV infected cells can survive in spite of an effective ART treatment.
Keywords: Antibody, antiretroviral therapy, b cell, HIV, Tat, vaccine, cellular immunity, HIV infected cells, anti Tat IgG, patients
Infectious Disorders - Drug Targets
Title: Antiretroviral Therapy Does Not Block the Secretion of the Human Immunodeficiency Virus Tat Protein
Volume: 12 Issue: 1
Author(s): Catherine Tamalet, Erwann P. Loret, Grant R. Campbell, Stephen A. Spector, Philippe Brouqui, Andreas Stein, Francoise Dignat-George, Pascale Paul, Corinne Brunet, Sonia Mediouni, Herve Moreau, Malika Mokhtari, Herve Tissot-Dupont, Catherine Dhiver, Isabelle Ravaux, Gilbert Baillat and Albert Darque
Affiliation:
Keywords: Antibody, antiretroviral therapy, b cell, HIV, Tat, vaccine, cellular immunity, HIV infected cells, anti Tat IgG, patients
Abstract: Tat is a viral protein secreted from HIV infected cells and extra cellular Tat is suspected to prevent destruction of HIV infected cells from cells of the cellular immunity. The effect of anti retroviral therapy (ART) on Tat secretion has never been investigated. In this study, we tested for antibody reactivity against Tat variants representative of the main HIV subtypes in HIV positive patients receiving ART with undetectable viral loads ( < 40 copies/mL) over the course of one year with a blood sampling every three months. For each of theses five blood sampling, an average of 50 % of patients had Anti-Tat IgG, it turned out that 86% of patients could recognize Tat at least in one blood sampling during the course of the study. Amazingly, anti-Tat IgG appeared and/or disappeared in 66 % of patients. Only 20% had anti-Tat IgG remaining persistently while 14% were consistently without anti Tat IgG in the five blood sampling. No significant correlation was found between anti-Tat IgG and CD4+ T cell, CD8+ T cell and B cell counts revealing the incapacity of these anti Tat IgG to neutralize extra cellular Tat. Interestingly the absence and then the appearance of anti-Tat IgG in patients suggest the presence of HIV infected cells in the blood that may constitute a significant reservoir of HIV infected cells. As a conclusion antiretroviral therapy does not block the secretion of Tat and may explain why HIV infected cells can survive in spite of an effective ART treatment.
Export Options
About this article
Cite this article as:
Tamalet Catherine, P. Loret Erwann, R. Campbell Grant, A. Spector Stephen, Brouqui Philippe, Stein Andreas, Dignat-George Francoise, Paul Pascale, Brunet Corinne, Mediouni Sonia, Moreau Herve, Mokhtari Malika, Tissot-Dupont Herve, Dhiver Catherine, Ravaux Isabelle, Baillat Gilbert and Darque Albert, Antiretroviral Therapy Does Not Block the Secretion of the Human Immunodeficiency Virus Tat Protein, Infectious Disorders - Drug Targets 2012; 12 (1) . https://dx.doi.org/10.2174/187152612798994939
DOI https://dx.doi.org/10.2174/187152612798994939 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
T-Regulatory Cell Subsets in Children with Type 1 Diabetes Mellitus: Relation to Control of the Disease
Endocrine, Metabolic & Immune Disorders - Drug Targets Psychobiome Feeding Mind: Polyphenolics in Depression and Anxiety
Current Topics in Medicinal Chemistry Rexinoids for Prevention and Treatment of Cancer: Opportunities and Challenges
Current Topics in Medicinal Chemistry Malaria Stage-Specific Vaccine Candidates
Current Pharmaceutical Design Editorial [ Inflammatory Bowel Disease and Inflammation-Associated Colon Cancer:Partners in Crime Guest Editor: Silvio Danese ]
Current Drug Targets Pharmacokinetic Interaction Between Verapamil and Methylxanthine Derivatives in Mice
Drug Metabolism Letters Effects of Gene and Plasma Tau on Cognitive Impairment in Rural Chinese Population
Current Alzheimer Research An Overview of Natural Plant Products in the Treatment of Hepatocellular Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Biologics: An Update and Challenge of Their Pharmacokinetics
Current Drug Metabolism Inhibition of Apoptosis in Pediatric Cancer by Survivin
Current Pediatric Reviews Leptin and the Ob-Receptor as Anti-Obesity Target: Recent In Silico Advances in the Comprehension of the Protein-Protein Interaction and Rational Drug Design of Anti- Obesity Lead Compounds
Current Pharmaceutical Design The Causal Relationship Between Passive Smoking and Inflammation on the Development of Cardiovascular Disease: A Review of the Evidence
Inflammation & Allergy - Drug Targets (Discontinued) Synthetic Strategies Towards Safer NSAIDs Through Prodrug Approach: A Review
Mini-Reviews in Medicinal Chemistry Cytokines in the Thymus: Production and Biological Effects
Current Medicinal Chemistry HLA-G Molecule
Current Pharmaceutical Design Molecular Genetics and Targeted Therapy in Hepatocellular Carcinoma
Current Cancer Drug Targets Innate Immune Surveillance in the Central Nervous System Following Legionella pneumophila Infection
CNS & Neurological Disorders - Drug Targets Potential Drug Targets Against Hepatitis B Virus Based on Both Virus and Host Factors
Current Drug Targets Nanotechnology for Delivery of Drugs and Biomedical Applications
Current Clinical Pharmacology The Tumor Necrosis Factor-Derived TIP Peptide: A Potential Anti-Edema Drug
Letters in Drug Design & Discovery